207 related articles for article (PubMed ID: 32470182)
1. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.
Abulfathi AA; Donald PR; Adams K; Svensson EM; Diacon AH; Reuter H
Br J Clin Pharmacol; 2020 Nov; 86(11):2123-2132. PubMed ID: 32470182
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
[TBL] [Abstract][Full Text] [Related]
3. Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi AA; Assawasuwannakit P; Donald PR; Diacon AH; Reuter H; Svensson EM
Eur J Clin Pharmacol; 2020 Nov; 76(11):1557-1565. PubMed ID: 32588106
[TBL] [Abstract][Full Text] [Related]
4. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.
Sy SK; de Kock L; Diacon AH; Werely CJ; Xia H; Rosenkranz B; van der Merwe L; Donald PR
Antimicrob Agents Chemother; 2015 Jul; 59(7):4129-38. PubMed ID: 25963985
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR
Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
[TBL] [Abstract][Full Text] [Related]
7. Para-aminosalicylic acid: the return of an old friend.
Donald PR; Diacon AH
Lancet Infect Dis; 2015 Sep; 15(9):1091-1099. PubMed ID: 26277036
[TBL] [Abstract][Full Text] [Related]
8. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.
Kibleur Y; Brochart H; Schaaf HS; Diacon AH; Donald PR
Clin Drug Investig; 2014 Apr; 34(4):269-76. PubMed ID: 24488376
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism].
Mizutani H; Horiba M; Shindoh J; Kimura T; Son M; Wakahara K
Kekkaku; 2001 Oct; 76(10):667-72. PubMed ID: 11712388
[TBL] [Abstract][Full Text] [Related]
10. Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis.
Wilson JW; Kelkar P; Frigas E
Int J Tuberc Lung Dis; 2003 May; 7(5):493-7. PubMed ID: 12757053
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Peloquin CA; Henshaw TL; Huitt GA; Berning SE; Nitta AT; James GT
Pharmacotherapy; 1994; 14(1):40-6. PubMed ID: 8159600
[TBL] [Abstract][Full Text] [Related]
12. Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
Peloquin CA; Berning SE; Huitt GA; Childs JM; Singleton MD; James GT
Am J Respir Crit Care Med; 1999 Mar; 159(3):932-4. PubMed ID: 10051275
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Hegde PV; Howe MD; Zimmerman MD; Boshoff HIM; Sharma S; Remache B; Jia Z; Pan Y; Baughn AD; Dartois V; Aldrich CC
Eur J Med Chem; 2022 Mar; 232():114201. PubMed ID: 35219151
[TBL] [Abstract][Full Text] [Related]
14. Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.
Wang W; Li S; Ge Q; Guo H; Shang Y; Ren W; Wang Y; Xue Z; Lu J; Pang Y
Ann Clin Microbiol Antimicrob; 2022 Nov; 21(1):48. PubMed ID: 36335391
[TBL] [Abstract][Full Text] [Related]
15. Successful oral desensitization to i.v. para-aminosalicylic acid (PAS) using encapsulated PAS dry substance.
Vesenbeckh SM; Becker J; Huhnt C; Karras B; Bauer TT; Mauch H; Rüssmann H; Schönfeld N
Infection; 2012 Apr; 40(2):199-202. PubMed ID: 21833615
[TBL] [Abstract][Full Text] [Related]
16. Development of a highly biocompatible antituberculosis nanodelivery formulation based on para-aminosalicylic acid-zinc layered hydroxide nanocomposites.
Saifullah B; Arulselvan P; El Zowalaty ME; Fakurazi S; Webster TJ; Geilich B; Hussein MZ
ScientificWorldJournal; 2014; 2014():401460. PubMed ID: 25050392
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Prasad R; Verma SK; Sahai S; Kumar S; Jain A
Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
[TBL] [Abstract][Full Text] [Related]
18. [Clinical pharmacokinetics of para-aminosalicylic acid tablets].
Miroshnichenko II; Sokolova GB; Mokhireva LV
Antibiot Khimioter; 2009; 54(1-2):20-4. PubMed ID: 19499713
[TBL] [Abstract][Full Text] [Related]
19. French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS(®) in MDR-TB patients.
Kibleur Y; Veziris N
Chemotherapy; 2014; 60(3):174-9. PubMed ID: 25823752
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resistant Mycobacterium tuberculosis isolates in China.
Li G; Zhang J; Jiang Y; Zhao LL; Liu H; Li M; Zhao X; Wan K
J Glob Antimicrob Resist; 2020 Mar; 20():275-281. PubMed ID: 31425771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
